Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 41, 3891-3895, October 1, 1981]
© 1981 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roberts, D.
Right arrow Articles by Karas, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roberts, D.
Right arrow Articles by Karas, J. G.

Response of L1210 Leukemia to Treatment with 1,3-Bis(2-chloroethyl)-1-nitrosourea plus 4'-Demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-ß-D-glucopyranoside)1

DeWayne Roberts2, Charles Peck, Susan Hilliard and James G. Karas

Departments of Biochemical and Clinical Pharmacology [D. R., C. P., S. H.] and Biostatistics [J. G. K.], St. Jude Children's Research Hospital, Memphis, Tennessee 38101

Mice, inoculated i.p. with 1 million L1210 ascites cells, were treated subsequently with 1,3-bis(2-chloroethyl)-1-nitrosourea plus 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-ß-D-glucopyranoside) in various combinations of dosages. The drugs were administered i.p. in rapid succession on one of four schedules. When treatment was administered on Day 1, 24 hr after inoculation, all mice treated with one of five combinations of dosages survived for 60 days, apparently free of leukemia, and another 16 combinations of the drugs cured 50%, or more, of the animals. Treatment with combinations of lower dosages of the drugs on Days 1, 4, and 7 was as effective as treatment with larger dosages on Day 1; all mice treated with 5 combinations of the drugs survived, and 17 other combinations cured 50%, or more, of the mice.

When mice were treated on similar schedules but the initiation of treatment was delayed until Day 4, the therapeutic efficacy of the individual drugs and of the combinations decreased. Some of the mice survived for 60 days after treatment with both drugs on Day 4, but the incidence was not greater than that achieved by treatment with the optimal dosage of 1,3-bis(2-chloroethyl)-1-nitrosourea on Day 4. The schedule of treatment on Days 4, 7, and 10 was the least effective, therapeutically, of the four schedules tested; only 12 of 235 mice survived for 60 days after treatment with the individual drugs or the drug combination. Because of a termination of the studies after 60 days, the data for all four studies were analyzed by the Cox multiple-regression technique. By this criterion, the incidence of mortality after treatment with the drugs on either Day 1 or Days 1, 4, and 7 was attributable in part to a therapeutic interaction between the drugs. This therapeutic interaction was not observed when mice were treated once on Day 4. Analysis of the incidence of mortality after three courses of treatment, i.e., treatment on Days 4, 7, and 10, indicated that, although each drug was oncolytic, an interaction between the drugs reduced the effectiveness of the combination. 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-ß-D-glucopyranoside) plus 1,3-bis(2-chloroethyl)-1-nitrosourea was remarkably effective for the treatment of L1210 leukemia, and on certain schedules the effectiveness resulted from a therapeutic interaction between the drugs.

1 This investigation was supported by Research Project Grants CA-12732 and CA-23337 and by Cancer Center Support (Core) Grant CA-21765 from the National Cancer Institute, NIH, Department of Health, Education and Welfare, and by the American Lebanese Syrian Associated Charities.

2 To whom requests for reprints should be addressed, at the Department of Biochemical and Clinical Pharmacology, St. Jude Children's Research Hospital, P. O. Box 318, Memphis, Tenn. 38101.

Received 3/10/80. Accepted 7/10/81.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1981 by the American Association for Cancer Research.